Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice-Reference-Cited by-同舟云学术

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

Published:2018-09-05 Issue:4 Volume:101 Page:556-565
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Terpos Evangelos¹^ORCID,Katodritou Eirini²,de la Rubia Javier³,Hungria Vania²,Hulin Cyrille⁴,Roussou Maria¹,Delforge Michel⁵,Bries Greet⁶,Stoppa Anne-Marie⁷,Aagesen Jesper⁸,Sargin Deniz⁹,Belch Andrew¹⁰,Ahlberg Lucia¹¹,Diels Joris¹²,Olie Robert A.¹³,Robinson Don¹⁴,Spencer Mike¹⁵,Potamianou Anna¹⁶,van de Velde Helgi¹⁷,Dimopoulos Meletios A.¹

Affiliation:

1. Department of Clinical Therapeutics; National and Kapodistrian University of Athens School of Medicine; Athens Greece

2. Department of Hematology; Theagenion Cancer Centre; Thessaloniki Greece

3. Department of Hematology; Hospital Dr Peset; Universidad Católica de Valencia; Valencia Spain

4. Service d'hématologie Hopital Haut leveque CHU Bordeaux; Bordeaux France

5. Department of Hematology; University Hospital Leuven; Leuven Belgium

6. Department of Hematology; AZ Turnhout; Turnhout Belgium

7. Département D'Onco-Hématologie; Institut Paoli-Calmettes; Marseilles France

8. Department of Medicine; Ryhov County Hospital; Jönköping Sweden

9. Division of Hematology; Department of Internal Medicine; Istanbul University; Istanbul Turkey

10. Department of Oncology; Cross Cancer Institute; Edmonton AB Canada

11. Hematologliniken Universitetssjukhuset; Linköping Sweden